Sign In
Buy ATAI
$4.53
-0.280 (-5.82%)
At Close: Jun 03, 2026
atai Launches Revixia Life Sciences to Develop Salvinorin A for a Variety of Mental Health Conditions
08:50am, Thursday, 12'th Aug 2021
BERLIN, Aug. 12, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences (Nasdaq: ATAI) ("atai"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, annou
BERLIN, Aug. 09, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders,
atai Life Sciences to Present at the 41st Annual Canaccord Genuity Growth Conference
06:10pm, Friday, 06'th Aug 2021
BERLIN, Aug. 06, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders,
Atai Launches New "Nose-To-Brain" Drug Delivery Company To Interact With Its Portfolio Of Psychedelics Subsidiaries
05:32pm, Wednesday, 28'th Jul 2021
Atai Life Sciences (NASDAQ:ATAI) is launching a new company that will interact with its portfolio of psychedelics and tech start-ups looking at novel mental health treatments. InnarisBio Inc., as the
BERLIN and BRISBANE, Australia, July 28, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences (“atai” or the “Company”) (Nasdaq: ATAI), a clinical-stage biopharmaceutical company aiming to transform t
This week, a number of financial firms and investment banks initiated coverage of Atai Life Sciences (NASDAQ:ATAI), the Peter Thiel-backed biotech exploring a host of psychedelic compounds and treatm
Leading U.S.-Based Psychedelic Healthcare VC Fund Launches with $35 Million Raised to Tackle the Growing Global Mental Health Crisis
09:00am, Thursday, 15'th Jul 2021
CHICAGO, July 15, 2021 /PRNewswire/ -- P alo Santo , the leading U.S.-based psychedelic investment fund, announced its launch with an initial $35 million in capital raised and an active portfolio of
Chewy, Brinker, Cleveland-Cliffs, Nvidia and More Thursday Afternoon Analyst Calls
12:21pm, Thursday, 08'th Jul 2021
With the trading day more than halfway over, the broad markets saw a loss across the board.
atai Life Sciences to Present at the Cowen Psychedelics & Novel Mechanisms in Neuropsychiatry Summit
07:47pm, Wednesday, 07'th Jul 2021
BERLIN, Germany, July 07, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company developing psychedelic and non-psychedelic compounds
Got $1,000? Consider This Freshly IPO'd Psychedelic Biotech
06:40am, Saturday, 03'rd Jul 2021
It's off to a running start.
5 Stocks With High Insider Interest
09:40pm, Thursday, 01'st Jul 2021
Unique insider buys at high levels through the second quarter
Peter Thiel-backed Psychedelics Company Rings Nasdaq Bell: Atai Life Sciences Goes Public
04:59pm, Friday, 18'th Jun 2021
Atai Life Sciences (NASDAQ:ATAI), a biotech company in the psychedelic space, had its Nasdaq debut on Friday. The Berlin-based company is joining an exclusive group of start-ups in the psychedelics se
Peter Thiel-backed psychedelic start-up's shares pop in Wall Street debut
02:30pm, Friday, 18'th Jun 2021
The German biotech's initial public offering was priced Thursday night at $15 per share, the high end of the expected range.
Peter Thiel's Atai Life Sciences and 5 Other Companies List Shares
02:21pm, Friday, 18'th Jun 2021
Going public on Friday: atai Life Sciences, Ambrx Biopharma, Century Therapeutics, Codex DNA, Cyteir Therapeutics, and Femasys.
Thiel-backed psychedelic drugmaker valued at $3.2B in Nasdaq debut
02:02pm, Friday, 18'th Jun 2021
Shares of Atai Life Sciences, backed by billionaire investor Peter Thiel, surged 40 percent in their U.S. stock market debut on Friday, giving the German psychedelics startup a market capitalization
